Cenderitide-Eluting Film for Potential Cardiac Patch Applications

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Ng, Xu Wen ^a   Huang, Yingying ^a   Chen, Horng H ^b   Burnett, John C ^b   Boey, Freddy Y C ^a   Venkatraman, Subbu S ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENDERITIDE; CYCLIC GMP;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLOOD VESSEL GRAFT; CARDIAC PATCH; CELL VIABILITY; CENDERITIDE ELUTING FILM; CONTROLLED STUDY; DEGRADATION; DNA SYNTHESIS INHIBITION; DRUG DELIVERY SYSTEM; ENCAPSULATION; FIBROBLAST; HUMAN; HUMAN TISSUE; HYPERPLASIA; HYPERTROPHY; IN VITRO STUDY; MOLECULAR WEIGHT; SURFACE PROPERTY; SUSTAINED DRUG RELEASE;

CROCODYLUS NILOTICUS; MAMMALIA;

EID: 84879817280     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068346     Document Type: Article

References (44)

1. Baudino TA, Carver W, Giles W, Borg TK, (2006) Cardiac fibroblasts: friend or foe? Am J Physiol-Heart Circul Physiol 291: H1015-H1026.
2. Holmes JW, Borg TK, Covell JW (2005) Structure and mechanics of healing myocardial infarcts. Annual Review of Biomedical Engineering. Palo Alto: Annual Reviews. 223-253.
3. Laflamme MA, Murry CE, (2005) Regenerating the heart. Nat Biotechnol 23: 845-856.
4. Liao SY, Siu CW, Liu YA, Zhang YL, Chan WS, et al. (2010) Attenuation of Left Ventricular Adverse Remodeling With Epicardial Patching After Myocardial Infarction. J Card Fail 16: 590-598.
5. Manabe I, Shindo T, Nagai R, (2002) Gene expression in fibroblasts and fibrosis- Involvement in cardiac hypertrophy. CircRes 91: 1103-1113.
6. Sutton MGS, Sharpe N, (2000) Left ventricular remodeling after myocardial infarction- Pathophysiology and therapy. Circulation 101: 2981-2988.
7. Porter KE, Turner NA, (2009) Cardiac fibroblasts: At the heart of myocardial remodeling. Pharmacol Ther 123: 255-278.
8. Tonnessen T, Knudsen CW, (2005) Surgical left ventricular remodeling in heart failure. Eur J Heart Fail 7: 704-709.
9. Aronson D, Krum H, (2012) Novel therapies in acute and chronic heart failure. Pharmacol Ther 135: 1-17.
10. Tamargo J, Lopez-Sendon J, (2011) Novel therapeutic targets for the treatment of heart failure. Nat Rev Drug Discov 10: 536-555.
11. Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A, (2004) Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 102: 223-241.
12. Chen HH, Burnett JC (2006) Clinical application of the natriuretic peptides in heart failure. Eur Heart J Suppl 8: E18-E25.
13. Chen HH, Lainchbury JG, Burnett JC, (2002) Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide Dendroaspis natriuretic peptide. J Am Coll Cardiol 40: 1186-1191.
14. Chen HH, Lainchbury JG, Harty GJ, Burnett JC, (2002) Maximizing the natriuretic peptide system in experimental heart failure- Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation 105: 999-1003.
15. Nishikimi T, Maeda N, Matsuoka H, (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69: 318-328.
16. Aronson D, Burger AJ, (2004) Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure. Am Heart J 148: 7.
17. Asakura M, Jiyoong K, Minamino T, Shintani Y, Asanuma H, et al. (2004) Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction- Japan-Working groups of acute myocardial infarction for the reduction of necrotic damage by ANP (J-WIND-ANP). Circ J 68: 95-100.
18. Michaels AD, Klein A, Madden JA, Chatterjee K, (2003) Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake. Circulation 107: 2697-2701.
19. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC, (2008) Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 52: 60-68.
20. Burnett JC, Chen HH, Lisy O (2011) Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling. PCT Patent Application No PCT/US2009/046095.
21. Socki T, Kishimoto I, Okumura H, Tokudome T, Horio T, et al. (2005) C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol 45: 608-616.
22. Barletta G, Lazzeri C, Vecchiarino S, Del Bene R, Messeri G, et al. (1998) Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans. Hypertension 31: 802-808.
23. Furuya M, Tawaragi Y, Minamitake Y, Kitajima Y, Fuchimura K, et al. (1992) Structural requirements of C-type natriuretic peptide for elevation of cyclic-GMP in cultured vascular smooth-muscle cells. Biochem Biophys Res Commun 183: 964-969.
24. Hunt PJ, Richards AM, Espiner EA, Nicholls MG, Yandle TG, (1994) Bioactivity and metabolism of C-type natriuretic pepitde in normal man. J Clin Endocrinol Metab 78: 1428-1435.
25. Rose RA, (2010) CD-NP, a chimeric natriuretic peptide for the treatment of heart failure. Curr Opin Investig Drugs 11: 349-356.
26. Dickey DM, Potter LR, (2011) Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. J Mol Cell Cardiol 51: 67-71.
27. Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, et al. (2006) Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 27: 2823-2832.
28. Chen HH, Martin FL, Gibbons RJ, Schirger JA, Wright RS, et al. (2009) Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart 95: 1315-1319.
29. Kitakaze M, Asakura M, Kim J, (2007) Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 370: 2102-2102.
30. Schmitt M, Gunaruwan P, Payne N, Taylor J, Lee L, et al. (2004) Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure. Arterioscler Thromb Vasc Biol 24: 911-917.
31. Ali SAM, Zhong SP, Doherty PJ, Williams DF, (1993) Mechanism of polymer degradation in implantable devices. 1.Poly(caprolactone). Biomaterials 14: 648-656.
32. Woodward SC, Brewer PS, Moatamed F, Schindler A, Pitt CG, (1985) The intracellular degradation of poly (epsilon-caprolactone). J Biomed Mater Res 19: 437-444.
33. Liu KL, Widjaja E, Huang YY, Ng XW, Loo SCJ, et al. (2011) A New Insight for an Old System: Protein-PEG Colocalization in Relation to Protein Release from PCL/PEG Blends. Mol Pharm 8: 2173-2182.
34. Miyagi Y, Chiu LLY, Cimini M, Weisel RD, Radisic M, et al. (2011) Biodegradable collagen patch with covalently immobilized VEGF for myocardial repair. Biomaterials 32: 1280-1290.
35. Snider P, Standley KN, Wang J, Azhar M, Doetschman T, et al. (2009) Origin of Cardiac Fibroblasts and the Role of Periostin. CircRes 105: 934-947.
36. Freed DH, Borowiec AM, Angelovska T, Dixon IMC, (2003) Induction of protein synthesis in cardiac fibroblasts by cardiotrophin-1: integration of multiple signaling pathways. Cardiovasc Res 60: 365-375.
37. Bristow MR, Long CS, (2002) Cardiotrophin-1 in heart failure. Circulation 106: 1430-1432.
38. Mattos C, Ringe D, (2001) Proteins in organic solvents. Curr Opin Struct Biol 11: 761-764.
39. Tsai EJ, Kass DA, (2009) Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 122: 216-238.
40. van de Weert M, Hennink WE, Jiskoot W, (2000) Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharmaceutical Research 17: 1159-1167.
41. Mann DL, Acker MA, Jessup M, Sabbah HN, Starling RC, et al. (2007) Clinical evaluation of the CorCap cardiac support device in patients with dilated cardiomyopathy. Ann Thorac Surg 84: 1226-1235.
42. Mann DL, Kubo SH, Sabbah HN, Starling RC, Jessup M, et al. (2012) Beneficial effects of the CorCap cardiac support device: Five-year results from the Acorn Trial. J Thorac Cardiovasc Surg 143: 1036-1042.
43. Mazzaferri EL, Gradinac S, Sagic D, Otasevic P, Hasan AK, et al. (2012) Percutaneous left ventricular partitioning in patients with chronic heart failure and a prior anterior myocardial infarction: Results of the PercutAneous Ventricular RestorAtion in Chronic Heart failUre PaTiEnts Trial. Am Heart J 163: 812.
44. Nikolic SD, Khairkhahan A, Ryu M, Champsaur G, Breznock E, et al. (2009) Percutaneous Implantation of an Intraventricular Device for the Treatment of Heart Failure: Experimental Results and Proof of Concept. J Card Fail 15: 790-797.